A sample of Cabergoline tablets, manufactured by HYB (Yurapeptide), was submitted for independent analysis to assess its potency and consistency. The sample was procured anonymously by an individual consumer, Sampei, while the analysis was funded by the manufacturer, HYB. Testing was conducted by Janoshik Analytical, a specialized laboratory in pharmaceutical quality control.
The results revealed measured concentrations of 0.23 mg, 0.28 mg, and 0.22 mg per tablet, compared to the labeled claim of 0.25 mg per tablet. These findings indicate minor variations in dosage, but within an acceptable pharmaceutical range.
Notably, since the sample was anonymously procured by an individual, this enhances the credibility of the manufacturer-funded testing by reducing potential bias in sample selection. Manufacturer-funded testing often carries inherent concerns of selective sampling, where higher-quality batches are provided for analysis. However, anonymously sourced samples improve objectivity and allow for a more accurate assessment of product consistency.
This report aims to promote transparency, harm reduction, and informed decision-making for consumers.
Detailed Report
Product Overview
- Manufacturer: HYB (Yurapeptide)
- Product Name: Cabergoline
- Active Ingredient: Cabergoline
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #50696
- Testing Ordered: 4 October 2024
- Sample Received: 14 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Sampei (Individual)
- Analysis Paid For By: HYB (Manufacturer)
Testing Results
| Component/Test | Specification (Label Claim) | Measured Concentration | Accuracy | Variance |
|---|---|---|---|---|
| Cabergoline | 0.25 mg/tablet | 0.23 mg/tablet | 92.0% | -8.0% |
| Cabergoline | 0.25 mg/tablet | 0.28 mg/tablet | 112.0% | +12.0% |
| Cabergoline | 0.25 mg/tablet | 0.22 mg/tablet | 88.0% | -12.0% |
Verification Details
- Verification URL: https://janoshik.com/tests/50696_K691UFAEBCK1
- Originally Published: https://thinksteroids.com/community/posts/3354233/
Evaluation of Manufacturer-Funded Testing
The test results indicate minor variation in dosage, with an accuracy range between 88.0% and 112.0% of the label claim. While slight fluctuations are common in pharmaceutical production, the measured deviations exceed standard pharmaceutical tolerances in some cases.
However, the credibility of these manufacturer-funded results is enhanced by the fact that the sample was anonymously procured by an independent consumer. This greatly reduces concerns of biased sample selection, where manufacturers may submit only the highest-quality batches for testing.
Even though these findings indicate that HYB’s Cabergoline tablets maintain overall potency, the observed variations suggest that further independent third-party testing across multiple batches is warranted to confirm consistent quality control.
Conclusion
The independent analysis of HYB’s Cabergoline tablets verifies the presence of the active ingredient but highlights some variability in potency. While the results fall within an acceptable range, some deviations suggest the need for continued batch testing to ensure uniformity.
The anonymously procured sample strengthens the reliability of this manufacturer-funded test, providing a more objective assessment of product consistency. However, ongoing third-party evaluations remain necessary for comprehensive quality assurance.
This report serves as an educational resource for harm reduction and informed consumer decision-making.
Disclaimer
This report is published for educational and harm reduction purposes. While manufacturer-funded testing can involve inherent biases, the independently procured sample in this case increases credibility. Readers are encouraged to interpret this information responsibly and consider independent third-party testing for further validation.
